Urinary Flow (Men's): A Nutritional and Natural-Health Reference
1. Definition and Overview
Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth or hyperplasia of prostate tissue and is a common cause of lower urinary tract symptoms (LUTS) in older men. In natural-health contexts, concerns about men's urinary flow most commonly center on the symptom complex associated with BPH and its associated lower urinary tract symptoms — a cluster of voiding complaints that substantially affect daily life and well-being.
To the pathologist, BPH is a microscopic diagnosis characterized by cellular proliferation of the stromal and epithelial elements of the prostate. To the practicing urologist, it represents a constellation of lower urinary tract symptoms (LUTS) that develop in the male population in association with aging and prostatic enlargement, presumably caused by bladder outlet obstruction (BOO). To the urodynamicist, the hallmark of BPH is the observation of synchronous elevated voiding pressure and a low urinary flow rate in the absence of other disease processes that cause BOO.
Distinct but related terminological designations exist in the literature. BPH describes the histological changes, benign prostatic enlargement (BPE) refers to the increased size of the gland (usually secondary to BPH), and bladder outlet obstruction is defined as the blockage to urinary flow. Those with BPE who present with bladder outlet obstruction are also termed benign prostatic obstruction.
2. How It Presents: Symptoms and Clinical Features
The clinical manifestations of BPH include lower urinary tract symptoms (LUTS), poor bladder emptying, urinary retention, detrusor instability, urinary tract infection, hematuria, and renal insufficiency. However, the majority of men with BPH present with LUTS only.
BPH is a progressive condition which results in increased frequency of urination, nocturia, a weak urine stream, hesitancy or delay in starting the urine flow, and incomplete bladder emptying. In one large epidemiological study of men aged 45 to 99 years, the overall prevalence of voiding disturbances included hesitancy in 9.1% of patients, weak stream in 30.5%, dribbling in 33.7%, sensation of incompletely emptied bladder in 26.4%, and nocturia in 56.1%.
A combination of storage, voiding, and post-micturition symptoms were present in 69% of subjects in one cross-sectional clinical study, and 30% showed more than two urgency episodes and more than six micturitions daily.
LUTS are typically classified into three subcategories:
- Voiding (obstructive) symptoms: weak or intermittent urinary stream, straining, hesitancy, terminal dribbling, incomplete emptying.
- Storage (irritative) symptoms: urinary frequency, urgency, nocturia, urge incontinence.
- Post-micturition symptoms: post-void dribbling and a sensation of incomplete bladder emptying.
Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder, an increased incidence of urinary tract infection, urinary stone formation, and renal failure.
3. Epidemiology and Prevalence
Up to 40% of men older than 50 years have lower urinary tract symptoms, including urinary urgency, nocturia, and weak urinary stream, due to disorders of the bladder and prostate. The histological prevalence of BPH at autopsy is as high as 50% to 60% for males in their 60s, increasing to 80% to 90% of those older than 70 years of age.
These symptoms negatively affect quality of life and may be associated with urinary retention, which can cause kidney insufficiency, bladder calculi, hematuria, and urinary tract infections.
4. Body Systems Involved
Men's urinary flow involves an interaction among several anatomical and physiological systems:
The Prostate and Urethra
Anatomically, the prostate is a fibromuscular and glandular organ that encircles the urethra at the bladder neck. It is situated in the true pelvis below the pubic bone and in front of the rectum. Its upper end (base) is continuous with the neck of the bladder, and its lower end (apex) rests on the pelvic floor. The urethra runs through the prostate from base to apex. Enlargement of this gland therefore directly compresses the urethral lumen, reducing flow.
The Bladder and Detrusor Muscle
In men, lower urinary tract symptoms can be caused by bladder outlet obstruction secondary to BPH, an overactive bladder detrusor (a syndrome of urinary urgency and frequency), or both. Over time, chronic obstruction induces structural changes in the bladder wall. Decreased elasticity and collagen in the prostatic urethra in men with BPH exacerbates symptoms of bladder outlet obstruction due to loss of compliance and increased flow resistance.
The Hormonal (Endocrine) System
The cause of the increase in prostatic volume is multifactorial, but current research has implicated hormonal aberrations. BPH is thought to involve a disruption of dihydrotestosterone (DHT)-supported homeostasis between cell proliferation and cell death; as a result, proliferative processes predominate and apoptotic processes are inhibited. Clinical data demonstrate that androgen suppression and α-blockade relieve symptoms and increase urinary flow rates in men with BPH.
The Autonomic Nervous System
The autonomic nervous system modulates prostatic smooth muscle tone via alpha-adrenergic receptors. Moderate long-term exercise reduces sympathetic nervous system activity at rest and decreases firing of sympathetic adrenergic neurons, which may dampen prostatic smooth muscle tone.
The Inflammatory System
BPH is characterized by the proliferation of prostatic epithelial and stromal cells, which leads to bladder outlet obstruction and exacerbation of lower urinary tract symptoms. There is increasing evidence that chronic prostatic inflammation contributes to the pathogenesis and progression of BPH.
5. Contributing and Associated Factors
Age
Disease prevalence has been shown to increase with advancing age. As prostate volume increases with age, the likelihood of acute urinary retention and symptom severity both increase while urinary flow rates fall. LUTS have been noted to have a recognizable progression pattern that worsens with age.
Metabolic Syndrome and Obesity
Single components of metabolic syndrome (obesity, dyslipidemia, hypertension, and insulin resistance) as well as the syndrome itself may predispose patients to a higher risk of BPH and lower urinary tract symptoms. This may stem from changes in insulin resistance, increased autonomic activity, impaired nitrergic innervation, increased Rho kinase activity, pro-inflammatory status, and changes in sex hormones that occur in association with metabolic syndrome.
Multiple studies have demonstrated a strong independent association between the components of metabolic syndrome and BPH/LUTS. Several modifiable factors involved in metabolic syndrome determinism, such as inadequate diet, lack of physical exercise, and smoking and drinking behaviours are emerging as main contributors to the development of BPH.
Diet and Nutrition
Lifestyle and metabolic factors associated with significantly increased risks of BPH and lower urinary tract symptoms include obesity, diabetes, and meat and fat consumption. Factors associated with decreased risks include physical activity, moderate alcohol intake, and vegetable consumption.
The Boston Area Community Health Study (2002–2005), a randomized population-based study, showed that a greater total energy intake was associated with higher LUTS symptom scores and an increased likelihood of storage symptoms. In addition to aging, various modifiable factors, including obesity, dietary choices, physical inactivity, hormonal imbalances, metabolic syndrome, and alcohol and tobacco use, contribute to the onset and progression of BPH, LUTS, or both.
Physical Activity
Results from the Health Professionals Follow-Up Study show that increasing levels of physical activity were associated with a lower risk of lower urinary tract symptoms independent of weight control. Data from the Massachusetts Male Aging Study found a similar inverse association between a man's exercise habits and his odds of clinical BPH.
If metabolic syndrome is related to the development of BPH/LUTS, lifestyle interventions including weight loss, a healthy diet, and physical activity would have a positive effect in both symptom relief and disease course.
Prostate Volume vs. Symptom Severity
Notably, the relationship between prostate size and symptom severity is not straightforward. A random population of men has the same mean prostate volume and distribution of prostate volumes as a group of age-matched men with clinical BPH, which provides further evidence that prostate size is relatively unimportant in the development of LUTS and bladder outlet obstruction.
6. Nutrients, Herbs, and Natural Ingredients
The use of some complementary health approaches such as phytotherapy for the treatment of lower urinary tract symptoms is common. Although there is limited evidence that some phytotherapeutic agents may help improve symptoms related to BPH over the short term, most of the trials conducted have been small in size, of short duration, and used varied doses and preparations.
Serenoa repens (Saw Palmetto)
Traditional use: Saw palmetto (Serenoa repens) is a small fan palm native to the southeastern United States. Its berries were used medicinally by Native American peoples of the southeastern region for food, as a tonic, and to address urogenital complaints. It subsequently entered European and American botanical medicine in the late 19th and early 20th centuries as a remedy for prostate and urinary difficulties in men.
Scientific evidence: Although several small studies have suggested modest benefit of saw palmetto for treating symptoms of BPH, a large study evaluating high doses of saw palmetto and a Cochrane review found that saw palmetto was not more effective than placebo for treatment of urinary symptoms related to BPH.
A 2023 review of 27 studies on saw palmetto in men with BPH found that this herb, when administered alone, provides little or no benefit for BPH symptoms. Because it had been suggested that saw palmetto products prepared using hexane extraction might be more effective than those prepared in other ways, reviewers analyzed studies of these products separately. No difference was found in the effects of the two kinds of products on BPH symptoms.
Specific trial detail: The NIH-funded Saw Palmetto Trial for Enlarged Prostates (STEP) found that a standard daily dose of 320 milligrams provided no greater symptom relief than placebo. A subsequent dose-escalation trial administered one, two, and then three 320 mg daily doses of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks; the primary outcome was the difference in AUA symptom index score from baseline to 72 weeks. This trial also found no significant benefit over placebo.
A 2012 Cochrane review of 32 randomized controlled trials involving 5,666 men with BPH found that Serenoa repens, at 2 and 3 times the usual dose, provides no improvement in urinary flow measures or prostate size in men with lower urinary tract symptoms consistent with BPH.
Combination use: A 2020 systematic review and meta-analysis involving 1,080 participants examined the effects of Serenoa repens (320 mg daily) with tamsulosin (0.4 mg daily) for BPH. The reviewers found that after at least the 6-month treatment cycle, Serenoa repens had the same effect as tamsulosin in treating BPH in terms of International Prostate Symptom Score. A single randomized controlled trial showed combination therapy of saw palmetto plus lycopene, selenium, and tamsulosin was more effective than single therapies alone. Specifically, the combination therapy significantly improved symptom scores at 6 months, and from 6 to 12 months demonstrated significant improvement in urine flow rate compared to tamsulosin alone.
Evidence strength: Overall weak to negative for saw palmetto as a standalone agent at standard doses, based on well-powered, NIH-funded randomized controlled trials and Cochrane systematic reviews. Evidence for combination approaches is preliminary.
Pygeum africanum (African Plum Tree Bark)
Traditional use: Pygeum africanum, derived from the bark of the African plum tree (Prunus africana), is used in traditional African medicine to alleviate urinary symptoms associated with BPH. Its use in traditional sub-Saharan African healing systems has been documented for centuries, where bark preparations were made as decoctions or powders to treat urinary difficulty.
Scientific evidence: The bioactive compounds, including phytosterols, triterpenes, and ferulic acid esters, exhibit anti-inflammatory and anti-androgenic properties that may reduce prostate enlargement and improve urinary flow dynamics.
A total of 18 randomized controlled trials involving 1,562 men met inclusion criteria and were analyzed in a Cochrane-level systematic review and meta-analysis by Ishani et al. (2000). Nocturia was reduced by 19%, residual urine volume by 24%, and peak urine flow was increased by 23%. Men using Pygeum africanum were more than twice as likely to report an improvement in overall symptoms as men getting the non-active placebo (65% with P. africanum vs. 30% with placebo; RR 2.1, 95% CI 1.4 to 3.1).
The evidence suggests that P. africanum modestly, but significantly, improves urologic symptoms and flow measures. Further research is needed using standardized preparations to determine its long-term effectiveness and ability to prevent complications associated with BPH.
The reviewed studies were small in size, were of short duration, used varied doses and preparations, and rarely reported outcomes using standardized validated measures of efficacy. Doses of Pygeum africanum used in the trials ranged between 75 to 200 mg per day.
Evidence strength: Moderate-quality evidence from a systematic review and meta-analysis of 18 RCTs supports modest improvements in urinary flow and nocturia. Studies are limited by short duration, small size, and lack of standardized preparation. Long-term safety data are limited.
Beta-Sitosterol
Traditional and nutritional context: Beta-sitosterol is a plant sterol found widely in seeds, nuts, vegetable oils, and cereal grains. Phytotherapeutic preparations containing beta-sitosterols, derived from the South African star grass (Hypoxis rooperi), or from species of Pinus and Picea, are available for the treatment of BPH. Its use as a specific prostate remedy has primarily developed in European herbal medicine and phytotherapy over the second half of the 20th century.
Scientific evidence: A Cochrane systematic review by Wilt et al. (1999) examined four randomized, double-blind, placebo-controlled trials in a total of 519 men. Beta-sitosterols improved urinary symptom scores and flow measures. The weighted mean difference (WMD) for the IPSS was −4.9 IPSS points (95% CI = −6.3 to −3.5, n = 2 studies). The WMD for peak urine flow was 3.91 mL/s (95% CI = 0.91 to 6.90, n = 4 studies) and the WMD for residual volume was −28.62 mL (95% CI = −41.42 to −15.83, n = 4 studies). Beta-sitosterols did not significantly reduce prostate size compared to placebo.
The evidence suggests non-glucosidic beta-sitosterols improve urinary symptoms and flow measures. Their long-term effectiveness, safety and ability to prevent BPH complications are not known.
Evidence strength: Moderate. Four RCTs of relatively short duration (4–26 weeks) showed meaningful improvements in flow rate and symptom scores, but long-term data are absent and the total evidence base has not been substantially updated since 1999.
Urtica dioica (Stinging Nettle Root)
Traditional use: Stinging nettle root (Urtica dioica) has a long history of use in European, particularly German and Central European, herbal traditions for urinary complaints associated with prostate enlargement. Root preparations were used in the form of aqueous or hydroalcoholic extracts and are incorporated in several approved European phytomedicines.
Scientific evidence: There is some limited evidence that Urtica dioica may improve some symptoms of BPH, including lower urinary tract symptoms. There is also some limited evidence that a combination of Urtica dioica and saw palmetto (Serenoa repens) may be efficacious for lower urinary tract symptoms associated with BPH.
One double-blind, randomized, placebo-controlled, crossover trial examined stinging nettle root for BPH. A separate study examined a combination of 25 mg Pygeum africanum and 300 mg stinging nettle extracts in a double-blind, randomized, placebo-controlled trial; the combination of 25 mg Pygeum africanum and 300 mg stinging nettle extracts produced clinical and urodynamic effects similar to placebo in that group of BPH patients. These results highlight the variable findings across combination preparations.
Evidence strength: Preliminary and inconsistent. Evidence from single trials and limited systematic reviews suggests possible modest benefit for urinary symptoms, but the body of evidence remains small and heterogeneous in terms of preparation and dose.
Cucurbita pepo (Pumpkin Seed / Pumpkin Seed Oil)
Traditional use: Pumpkin seed preparations have been used in folk medicine traditions across Central and Eastern Europe (particularly Germany and Austria) for urinary complaints associated with prostate conditions. In Germany, the Commission E has recognized pumpkin seed for supportive treatment of irritable bladder and micturition difficulties associated with BPH Stage I–II.
Scientific evidence: In a narrative review by Damiano et al., the role of Cucurbita pepo of the gourd family in the management of patients affected by LUTS due to BPH was summarized. Extracts of C. pepo appeared to show significant efficacy in improving urinary symptoms in clinical data. A single-blind randomized clinical trial at a urology clinic in Iran compared the effects of tamsulosin and pumpkin (Cucurbita pepo) seed oil on BPH symptoms, including patients aged ≥50 years with clinically diagnosed BPH. Pygeum africanum and pumpkin seeds demonstrated possible advantages with few negative effects in an overview of systematic reviews published up to 2025. Evidence for pumpkin seed oil is considered preliminary and effect sizes are generally modest.
Evidence strength: Preliminary. Available trials are small and of short duration. The evidence base is insufficient to make firm conclusions, though the tolerability profile is favorable.
Flower Pollen Extract (Rye Pollen / Secale cereale)
Traditional use: Pollen extracts, particularly those from rye grass (Secale cereale), have been used in European and Japanese naturopathic and integrative medicine traditions for prostate-related urinary symptoms since the 1970s.
Scientific evidence: Studies have demonstrated that pollen extracts show anti-inflammatory and anti-proliferative pharmacological effects. Research demonstrated that rye pollen is able to inhibit the synthesis of prostaglandin and leukotriene, performing an anticongestive and anti-inflammatory effect on the prostate tissue. Research has also highlighted a pharmacological effect of pollen extract on smooth muscles, which can be considered a therapeutic mechanism. Promising evidence from several clinical trials suggests that various preparations of a mix of flower pollens, prominently featuring rye pollen (Secale cereale L.), have potential benefits for prostate health and lower urinary tract symptoms in men.
Evidence strength: Preliminary to moderate for symptom reduction in prostatitis/CPPS; evidence for BPH is promising but limited by small trial sizes.
Lycopene
Nutritional context: Lycopene is a naturally occurring pigment that gives certain fruits and vegetables their red coloring. Tomatoes, watermelon, red oranges, pink grapefruit, apricots, rose hips, and guava all contain lycopene.
Scientific evidence in prostate health: Selenium, an essential trace element mainly functioning through selenoproteins and able to promote an optimal antioxidant/oxidant balance, and lycopene, a carotenoid, have been investigated alongside Serenoa repens for BPH. Phytotherapeutic agents, including Serenoa repens, have shown a role in ameliorating BPH/LUTS alone or in combination with selenium and lycopene. In a randomized, double-blind, placebo-controlled trial of 90 BPH patients, after 3 months, survivin and NAIP (anti-apoptotic proteins) were significantly decreased while caspase-3 was significantly increased in BPH patients treated with Serenoa repens–selenium–lycopene compared with the placebo group. These findings are molecular/mechanistic in nature and require further clinical translation.
Evidence strength: Preliminary. Most lycopene data relevant to the prostate address cancer risk rather than urinary flow per se. Combination trials involving lycopene show some promise but are not yet sufficient to establish lycopene as an independent agent for urinary flow improvement.
Selenium
Nutritional context: Selenium is an essential trace mineral incorporated into selenoproteins that regulate antioxidant defense and thyroid function. It is found in Brazil nuts, seafood, organ meats, and cereals.
Scientific evidence: As noted in the Serenoa repens/lycopene/selenium combination studies cited above, selenium appears to contribute antioxidant modulation to combination phytotherapy regimens. Phytotherapeutic agents including Serenoa repens have shown a role in ameliorating BPH/LUTS alone or in combination of other elements like selenium and lycopene. The evidence base for selenium as a standalone agent specifically for urinary flow is not well established, and most data exist in combination studies.
Evidence strength: Insufficient as a standalone agent for urinary flow. Combination trial data are preliminary.
Zinc
Nutritional context: The prostate gland normally contains higher concentrations of zinc than any other soft tissue in the body. Zinc is essential for androgen metabolism, cellular repair, and immune function.
Scientific evidence: There is some limited evidence on zinc and prostate-related outcomes from NCCIH. In vitro research has explored zinc's role in prostate cell biology, but human clinical trial evidence specifically demonstrating that zinc supplementation improves urinary flow in men with BPH is currently insufficient to draw firm conclusions. Zinc's role in prostate health is considered biologically plausible but clinically unconfirmed for urinary flow endpoints.
Evidence strength: Insufficient for urinary flow specifically. Biological rationale exists, but controlled human trial data are lacking.
7. Dietary and Lifestyle Factors
Dietary Patterns and Specific Foods
Type of diet and level of physical activity are now considered important factors affecting prostate health in the aging male. Emerging evidence indicates that, in addition to aging, various modifiable factors including obesity, dietary choices, physical inactivity, hormonal imbalances, metabolic syndrome, and alcohol and tobacco use contribute to the onset and progression of BPH, LUTS, or both.
Lifestyle and metabolic factors associated with significantly increased risks of BPH and LUTS include obesity, diabetes, and meat and fat consumption. Factors associated with decreased risks include physical activity, moderate alcohol intake, and vegetable consumption.
More frequent meat, fish, and egg intake decreased the total IPSS scores, while frequent milk and dairy product intake increased the total IPSS scores in Chinese men in one cross-sectional study. These findings are observational and require confirmation in prospective controlled studies.
Caloric Intake and Obesity
The Boston Area Community Health Study (2002–2005) showed that greater total energy intake was associated with higher LUTS symptom scores and an increased likelihood of storage symptoms. Overeating was also identified as a significantly adverse habit in relation to total LUTS, voiding symptoms, storage symptoms, and quality of life scores.
A lack of exercise, together with obesity, may lead to insulin resistance, exerting a detrimental effect on lipid ratios, decreasing blood levels of HDL cholesterol, and increasing blood levels of triglycerides and LDL cholesterol. These metabolic changes appear to compound the androgenic and inflammatory pathways implicated in BPH progression.
Physical Activity
Multiple studies have demonstrated a strong independent association between the components of metabolic syndrome and BPH/LUTS. Furthermore, modifiable risk factors such as increased physical activity appear to decrease the risk of BPH/LUTS.
Moderate long-term exercise reduces sympathetic nervous system activity at rest and decreases firing of sympathetic adrenergic neurons, which may dampen prostatic smooth muscle tone. Results from the Health Professionals Follow-Up Study show that increasing levels of physical activity were associated with a lower risk of lower urinary tract symptoms, independent of weight control.
Fluid Intake and Behavioral Approaches
Behavioral therapy, including pelvic floor physical therapy, timed voiding (voiding at specific intervals), and fluid restriction, can improve symptoms. While general adequate hydration supports overall urinary tract health, excess fluid intake — particularly late in the day — can worsen nocturia.
Alcohol and Smoking
Moderate alcohol intake has been associated with decreased risk of LUTS/BPH in epidemiological data, while for lipids and smoking no clear risk patterns have emerged. However, epidemiological associations between moderate alcohol and lower BPH risk should not be interpreted as a clinical recommendation; confounding is difficult to exclude in these observational studies.
Metabolic Syndrome Management
Increased physical activity and dietary strategies may help in decreasing the incidence of metabolic syndrome and its impact on BPH/LUTS. Lifestyle change, a healthy diet, and exercise might be enough to achieve symptom improvement and decrease the risk of cardiovascular disease in men with LUTS/BPH and metabolic syndrome.
8. Assessment Tools Referenced in the Literature
Assessment of symptom severity at baseline and during follow-up is performed using the American Urological Association Symptom Index (AUA-SI) or the International Prostate Symptom Score (IPSS). Uroflowometry is a simple, noninvasive, and useful test to detect the presence of bladder outlet obstruction and is the electronic recording of the urinary flow through the course of one voiding episode. These tools are the standard reference points against which natural interventions are measured in clinical research.
References
Go back